Filtros de búsqueda

Lista de obras de

A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization.

artículo científico publicado en 2017

A clinical update on the role of carfilzomib in the treatment of relapsed or refractory multiple myeloma

artículo científico publicado en 2016

A phase I/II minor histocompatibility antigen-loaded dendritic cell vaccination trial to safely improve the efficacy of donor lymphocyte infusions in myeloma

artículo científico

Accessory cells of the microenvironment protect multiple myeloma from T-cell cytotoxicity through cell adhesion-mediated immune resistance.

artículo científico publicado en 2013

Acute and chronic renal artery stenosis

artículo científico publicado en 2009

An European Myeloma Network recommendation on tools for diagnosis and monitoring of multiple myeloma: what to use and when

scholarly article by Jo Caers et al published 31 August 2018 in Haematologica

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

scientific article published on 03 June 2019

Brentuximab vedotin

artículo científico

CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance

CD38 antibodies in multiple myeloma: back to the future

artículo científico publicado en 2017

CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia

artículo científico publicado en 2018

CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma

artículo científico publicado en 2016

CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide

artículo científico publicado en 2020

CD38-targeted therapy with daratumumab reduces autoantibody levels in multiple myeloma patients

artículo científico publicado en 2019

CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience

artículo científico publicado en 2018

Carfilzomib versus bortezomib: no longer an ENDEAVOR

artículo científico publicado en 2017

Case report: persistently seronegative neuroborreliosis in an immunocompromised patient

scholarly article by Alex Wagemakers et al published 2 August 2018 in BMC Infectious Diseases

Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patients

scientific article published on 15 March 2018

Cerebrospinal Fluid Penetrance of Daratumumab in Leptomeningeal Multiple Myeloma

scientific article published on 15 July 2020

Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein

artículo científico publicado en 2003

Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma.

artículo científico publicado en 2015

Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells

artículo científico publicado en 2019

Continuous low-dose cyclophosphamide-prednisone is effective and well tolerated in patients with advanced multiple myeloma

artículo científico publicado en 2001

Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?

scientific article published on 06 February 2020

Could daratumumab be used to treat severe allergy?

scientific article published on 19 January 2017

Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update.

artículo científico publicado en 2017

Cytomegalovirus Reactivation in a Patient With Extensively Pretreated Multiple Myeloma During Daratumumab Treatment

scientific article published on 13 October 2018

Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma

artículo científico publicado en 2016

Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)

artículo científico publicado en 2020

Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials

artículo científico publicado en 2020

Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide

artículo científico publicado en 2014

Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab

scientific article published on 26 May 2020

Development of anti-CD32b antibodies with enhanced Fc function for the treatment of B and plasma cell malignancies

artículo científico publicado en 2020

Diagnosis and risk stratification in multiple myeloma

artículo científico

Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma

artículo científico publicado en 2016

Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome

artículo científico publicado en 2000

Dose-finding study of high-dose simvastatin combined with standard chemotherapy in patients with relapsed or refractory myeloma or lymphoma.

artículo científico publicado en 2006

Dual Targeting to Overcome Current Challenges in Multiple Myeloma CAR T-Cell Treatment

scientific article published on 05 August 2020

Editorial: Exploiting the Immune System to Treat Multiple Myeloma: From Transplantation to Novel Treatment Approaches

artículo científico publicado en 2020

Effect of conditioning regimens on graft failure in myelofibrosis: a retrospective analysis

artículo científico publicado en 2015

Effect of daratumumab on normal plasma cells, polyclonal immunoglobulin levels, and vaccination responses in extensively pre-treated multiple myeloma patients

artículo científico publicado en 2019

Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma

artículo científico publicado en 2017

Erratum to: Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma.

artículo científico publicado en 2016

European Myeloma Network guidelines for the management of multiple myeloma-related complications

artículo científico publicado en 2015

European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma

artículo científico publicado en 2014

European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias

artículo científico publicado en 2018

Extramedullary relapses after allogeneic non-myeloablative stem cell transplantation in multiple myeloma patients do not negatively affect treatment outcome.

artículo científico publicado en 2008

Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design.

artículo científico publicado en 2018

From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives

artículo científico publicado en 2018

G3139, a Bcl-2 antisense oligodeoxynucleotide, induces clinical responses in VAD refractory myeloma

artículo científico publicado en 2004

Geranylgeranylated proteins are involved in the regulation of myeloma cell growth.

artículo científico publicado en 2005

Growth factors and antiapoptotic signaling pathways in multiple myeloma

artículo científico publicado en 2005

Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study

artículo científico publicado en 2019

High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action

scientific article published on 11 December 2018

High-dose therapy and autologous stem cell transplantation in patients with POEMS syndrome: a retrospective study of the Plasma Cell Disorder sub-committee of the Chronic Malignancy Working Party of the European Society for Blood & Marrow Transplant ⬇️

artículo científico publicado en 2016

How I treat plasma cell leukemia

artículo científico publicado en 2012

Immunomodulatory effects of CD38-targeting antibodies

artículo científico publicado en 2018

Immunotherapy in multiple myeloma: when, where, and for who?

scientific article published on 26 August 2020

Immunotherapy in myeloma: how far have we come?

artículo científico publicado en 2019

Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myeloma.

artículo científico publicado en 2018

Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing Mcl-1 protein levels

artículo científico publicado en 2003

Inhibition of the mevalonate pathway potentiates the effects of lenalidomide in myeloma

artículo científico publicado en 2008

Insights on Multiple Myeloma Treatment Strategies

artículo científico publicado en 2018

Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA).

artículo científico publicado en 2016

International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders

scientific article published on 01 June 2019

Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II H

artículo científico publicado en 2020

Lenalidomide (Revlimid) combined with continuous oral cyclophosphamide (endoxan) and prednisone (REP) is effective in lenalidomide/dexamethasone-refractory myeloma

artículo científico publicado en 2010

Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients

Lenalidomide for the treatment of relapsed and refractory multiple myeloma.

artículo científico publicado en 2012

Leptomeningeal metastases from primary plasma cell leukemia

artículo científico publicado en 2013

Localized graft-versus-host disease of the skin provoked by radiotherapy

artículo científico publicado en 2010

Malignant transformation of monoclonal gammopathy of undetermined significance: cumulative incidence and prognostic factors.

artículo científico publicado en 2001

Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)

scientific article published on 22 May 2020

Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma

artículo científico publicado en 2016

Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference.

artículo científico publicado en 2016

Monoclonal antibodies in myeloma.

artículo científico

Monoclonal antibodies targeting CD38 in hematological malignancies and beyond

artículo científico publicado en 2016

Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma

artículo científico

Monoclonal gammopathy of renal significance (MGRS) histopathologic classification, diagnostic workup, and therapeutic options

artículo científico publicado en 2019

Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab

artículo científico publicado en 2017

Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

artículo científico publicado en 2017

New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients

artículo científico publicado en 2013

New developments in the treatment of patients with multiple myeloma

artículo científico publicado en 2010

New treatment strategies for multiple myeloma by targeting BCL-2 and the mevalonate pathway

artículo científico publicado en 2006

Oral proteasome inhibitor maintenance for multiple myeloma

scientific article published on 10 December 2018

Outcome of allogeneic transplantation in newly diagnosed and relapsed/refractory multiple myeloma: long-term follow-up in a single institution

artículo científico publicado en 2016

Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma

artículo científico publicado en 2016

Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial

artículo científico publicado en 2018

Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma

artículo científico publicado en 2016

Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma.

artículo científico publicado en 2016

Preclinical Activity of JNJ-7957, a Novel BCMA×CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab

scientific article published on 22 January 2020

Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib

artículo científico publicado en 2014

Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies

artículo científico publicado en 2020

Preclinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma

artículo científico publicado en 2015

Preclinical evidence for an effective therapeutic activity of FL118, a novel survivin inhibitor, in patients with relapsed/refractory multiple myeloma

artículo científico publicado en 2020

Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network

artículo científico publicado en 2017

Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network.

artículo científico publicado en 2018

Primary cardiac lymphoma with central nervous system relapse.

artículo científico publicado en 2017

Prognostic factors and outcome in relapsed multiple myeloma after nonmyeloablative allo-SCT: a single center experience

artículo científico publicado en 2010

Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma.

artículo científico publicado en 2006

Progressive neurological deficits in multiple myeloma: meningeal myelomatosis without MRI abnormalities.

artículo científico publicado en 2011

Protein geranylgeranylation is critical for the regulation of survival and proliferation of lymphoma tumor cells

artículo científico publicado en 2003

Rapidly progressive neurological deterioration without magnetic resonance imaging abnormalities: intravascular lymphoma

artículo científico publicado en 2014

Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network

artículo científico publicado en 2020

Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma

artículo científico publicado en 2006

Reprint of "Immunomodulatory effects of CD38-targeting antibodies"

scientific article published on 01 January 2019

Resistance Mechanisms Towards CD38-Directed Antibody Therapy in Multiple Myeloma

artículo científico publicado en 2020

Response to: Interference of daratumumab on the serum protein electrophoresis.

artículo científico publicado en 2016

Risk factors for hematological malignancy in polyneuropathy associated with monoclonal gammopathy

artículo científico publicado en 2001

Secondary monoclonal gammopathy of undetermined significance after allogeneic stem cell transplantation in multiple myeloma

artículo científico publicado en 2014

Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance.

artículo científico publicado en 2016

Sequencing multiple myeloma therapies with and after antibody therapies

artículo científico publicado en 2020

Should all newly diagnosed MM patients receive CD38 antibody-based treatment?

artículo científico publicado en 2020

Single-centre experience with nonmyeloablative allogeneic stem cell transplantation in patients with multiple myeloma: prolonged remissions induced

scientific article published on 01 May 2007

Smartphone measurements of physical activity and fitness are associated with early trial discontinuation of patients in (hemato)oncology phase I/II clinical trials

artículo científico publicado en 2020

Staphylococcus aureus pericardial abscess presenting as a localized bulge of the heart contour.

artículo científico publicado en 2010

Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO)

artículo científico publicado en 2020

Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma

scientific article published on 03 July 2019

T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma

artículo científico publicado en 2020

Takotsubo cardiomyopathy following radioiodine therapy for toxic multinodular goitre.

artículo científico publicado en 2009

Targeted Therapy With Immunoconjugates for Multiple Myeloma

artículo científico publicado en 2020

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

artículo científico publicado en 2015

Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial

artículo científico publicado en 2018

The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells

artículo científico publicado en 2002

The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network

artículo científico publicado en 2014

The impact of circulating suppressor cells in multiple myeloma patients on clinical outcome of DLIs.

artículo científico publicado en 2015

The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma

artículo científico publicado en 2004

Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group

scientific article published on 21 March 2016

Treatment of relapsed and refractory multiple myeloma in the era of novel agents

artículo científico publicado en 2010

Trogocytosis represents a novel mechanism of action of daratumumab in multiple myeloma

Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab.

artículo científico publicado en 2015

Validation of the FIRST simplified frailty scale using the ECOG performance status instead of patient-reported activities

scientific article published on 22 January 2020

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda